CPH to expand US footprint after USOTC listing
Finfeed Archived Jun 11, 2021
The US OTC listing gives Creso Pharma Ltd (ASX: CPH) greater exposure to a deeper capital market as well as greater access and liquidity for North American investors. Further to this, it provide additional opportunities to attract institutional and retail investors and for CPH to expand its investor base in the US.
Revenues up 237%: Creso Pharma delivers strong quarter ahead of OTC listing
Finfeed Archived Apr 30, 2021
There were several highlights to come out of the quarterly report released by Creso Pharma (ASX: CPH) today. CPH is enjoying a sustained run this year with revenues up 237% in the lead up to its US listing, which is expected to occur in the coming weeks.
Halucenex agreement to give CPH another leg up in psychedelics
Finfeed Archived Mar 31, 2021
Creso Pharma’s (ASX: CPH) pending acquisition of Halucenex Life Sciences should prove to be an astute move, with Halucenex continuing to rapidly move towards its goal of developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets.
$18M will help CPH progress near-term revenue initiatives
Finfeed Archived Mar 26, 2021
Creso Pharma (ASX: CPH) has received firm commitments to raise $18M, a sum that significantly shores up its balance sheet. CPH will use the funds to progress a number of value accretive opportunities including Phase II and Phase III clinical trial initiatives with target acquisition company Halucenex Life Sciences Inc.
CPH to list on the OTC as it expands North American footprint
Finfeed Archived Mar 23, 2021
Creso Pharma (ASX: CPH) today announced it is listing on the OTC market in the USA. Listing on the OTC is expected to unlock significant shareholder value and provides CPH with access to one of the largest investment markets in the world at nominal cost.